Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 1.08B 937M 877M 800M 1.51B 103B 1.53B 10.29B 4.03B 51.62B 4.06B 3.97B 172B P/E 2026 *
-14.5x
P/E 2027 * -13x
Enterprise Value 1.08B 937M 877M 800M 1.51B 103B 1.53B 10.29B 4.03B 51.62B 4.06B 3.97B 172B EV / Sales 2026 *
28.5x
EV / Sales 2027 * 54.3x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
1 day+1.25%
1 week-2.41%
Current month+5.19%
1 month+9.46%
3 months+5.19%
6 months+77.37%
Current year+111.30%
1 week 1.96
Extreme 1.96
2.49
1 month 1.96
Extreme 1.96
2.52
Current year 1.1
Extreme 1.1
2.68
1 year 1.03
Extreme 1.03
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 08/07/2024
Director of Finance/CFO 59 02/01/2025
Chief Tech/Sci/R&D Officer - 01/02/2025
Director TitleAgeSince
Chairman 83 01/01/2005
Chairman 71 27/02/2012
Director/Board Member 67 28/08/2007
Date Insider Type Main position Quantity % Market Cap.
2/28/26 A Fiscal year

General Counsel

651,031 0.1792%
2/28/26 A Fiscal year

Chief Executive Officer

1,211,357 0.3333%
2/28/26 A Fiscal year

Chief Financial Officer

375,355 0.1033%
Change 5-day change 1-year change 3-year change Capi.($)
+1.25%-2.41%+133.65%+40.46% 1.08B
-0.70%+13.34%+75.61%+103.83% 70.51B
-0.27%-0.21%+35.23%+63.42% 54.05B
-1.62%+34.25%+17.43%+491.04% 28.95B
-0.61%+12.51%+54.60%+7.40% 24.05B
0.00%+1.59%-15.06%-13.21% 23.31B
+9.77%+20.16%+260.17%+472.38% 18.67B
-0.46%+4.86%+43.35%-21.74% 18.37B
0.00%+7.46%+30.95%+623.97% 16.1B
-3.08%-8.34%+37.21%+138.52% 12.72B
Average +0.43%+356.26%+67.31%+190.61% 26.78B
Weighted average by Cap. +0.04%+348.74%+57.77%+168.42%

Financials

2026 *2027 *
Net sales 37.95M 32.88M 30.79M 28.09M 52.86M 3.62B 53.75M 361M 141M 1.81B 142M 139M 6.04B 19.91M 17.26M 16.16M 14.74M 27.74M 1.9B 28.21M 189M 74.22M 951M 74.77M 73.14M 3.17B
Net income -72.44M -62.77M -58.77M -53.62M -101M -6.91B -103M -689M -270M -3.46B -272M -266M -11.54B -90.96M -78.83M -73.8M -67.33M -127M -8.68B -129M -865M -339M -4.34B -342M -334M -14.49B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
11/08/26 $2.430 +1.25% 3,031,984
10/08/26 $2.400 -2.83% 2,696,711
07/08/26 $2.470 +4.66% 3,085,741
06/08/26 $2.360 -3.67% 4,890,832
05/08/26 $2.450 -1.61% 3,974,293
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.430USD
Average target price
3.856USD
Spread / Average Target
+58.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock